Cargando…
Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689529/ https://www.ncbi.nlm.nih.gov/pubmed/36359506 http://dx.doi.org/10.3390/diagnostics12112662 |
_version_ | 1784836557955399680 |
---|---|
author | Lu, Xiu-Yun Guo, Xi Zhang, Qi Qiu, Yi-Jie Zuo, Dan Chen, Sheng Tian, Xiao-Fan Zhou, Yu-Hong Dong, Yi Wang, Wen-Ping |
author_facet | Lu, Xiu-Yun Guo, Xi Zhang, Qi Qiu, Yi-Jie Zuo, Dan Chen, Sheng Tian, Xiao-Fan Zhou, Yu-Hong Dong, Yi Wang, Wen-Ping |
author_sort | Lu, Xiu-Yun |
collection | PubMed |
description | Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, patients with biopsy-proved and histopathologically proved LAPC who underwent regular CRT were recruited. DCE-US evaluations were performed before and four months after CRT. SonoVue-enhanced contrast-enhanced ultrasound (CEUS) was performed by an ultrasound system (ACUSON Sequoia; Siemens Medical Solutions, USA) equipped with a 5C1 MHz convex array transducer. Time–intensity curves were created by VueBox software (Bracco, Italy), and various DCE-US quantitative parameters were obtained. Taking Response Evaluation Criteria in Solid Tumors (RECIST) based on computed tomography (CT) or magnetic resonance imaging (MRI) as the gold standard, DCE-US parameters were compared between the treatment responder group (RG) and non-responder group (NRG). The correlation between the DCE-US parameters and the serum carbohydrate antigen 19-9 (CA 19-9) level was also analyzed. Results: Finally, 21 LAPC patients (mean age 59.3 ± 7.2 years) were included. In comparing the RG (n = 18) and NRG (n = 3), no significant change could be found among the mean size of the lesions (31.2 ± 8.1 mm vs. 27.2 ± 8.3 mm, p = 0.135). In comparing the TICs between the two groups, the LAPC lesions in the RG took a longer time to reach peak enhancement and to wash out. Among all the DCE-US parameters, RT (rise time), WiAUC (wash-in area under the curve), WoAUC (wash-out area under the curve) and WiWoAUC (wash-in and wash-out area under the curve) decreased significantly after CRT in the RG (p < 0.05). The RT ratio, WiAUC ratio, WoAUC ratio and WiWoAUC ratio were closely correlated with the change in serum CA 19-9 level in the RG (p < 0.05). Conclusion: DCE-US might be a potential imaging method for non-invasive follow-up for early response in LAPC patients treated by CRT. |
format | Online Article Text |
id | pubmed-9689529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96895292022-11-25 Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound Lu, Xiu-Yun Guo, Xi Zhang, Qi Qiu, Yi-Jie Zuo, Dan Chen, Sheng Tian, Xiao-Fan Zhou, Yu-Hong Dong, Yi Wang, Wen-Ping Diagnostics (Basel) Article Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, patients with biopsy-proved and histopathologically proved LAPC who underwent regular CRT were recruited. DCE-US evaluations were performed before and four months after CRT. SonoVue-enhanced contrast-enhanced ultrasound (CEUS) was performed by an ultrasound system (ACUSON Sequoia; Siemens Medical Solutions, USA) equipped with a 5C1 MHz convex array transducer. Time–intensity curves were created by VueBox software (Bracco, Italy), and various DCE-US quantitative parameters were obtained. Taking Response Evaluation Criteria in Solid Tumors (RECIST) based on computed tomography (CT) or magnetic resonance imaging (MRI) as the gold standard, DCE-US parameters were compared between the treatment responder group (RG) and non-responder group (NRG). The correlation between the DCE-US parameters and the serum carbohydrate antigen 19-9 (CA 19-9) level was also analyzed. Results: Finally, 21 LAPC patients (mean age 59.3 ± 7.2 years) were included. In comparing the RG (n = 18) and NRG (n = 3), no significant change could be found among the mean size of the lesions (31.2 ± 8.1 mm vs. 27.2 ± 8.3 mm, p = 0.135). In comparing the TICs between the two groups, the LAPC lesions in the RG took a longer time to reach peak enhancement and to wash out. Among all the DCE-US parameters, RT (rise time), WiAUC (wash-in area under the curve), WoAUC (wash-out area under the curve) and WiWoAUC (wash-in and wash-out area under the curve) decreased significantly after CRT in the RG (p < 0.05). The RT ratio, WiAUC ratio, WoAUC ratio and WiWoAUC ratio were closely correlated with the change in serum CA 19-9 level in the RG (p < 0.05). Conclusion: DCE-US might be a potential imaging method for non-invasive follow-up for early response in LAPC patients treated by CRT. MDPI 2022-11-02 /pmc/articles/PMC9689529/ /pubmed/36359506 http://dx.doi.org/10.3390/diagnostics12112662 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lu, Xiu-Yun Guo, Xi Zhang, Qi Qiu, Yi-Jie Zuo, Dan Chen, Sheng Tian, Xiao-Fan Zhou, Yu-Hong Dong, Yi Wang, Wen-Ping Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound |
title | Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound |
title_full | Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound |
title_fullStr | Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound |
title_full_unstemmed | Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound |
title_short | Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound |
title_sort | early assessment of chemoradiotherapy response for locally advanced pancreatic ductal adenocarcinoma by dynamic contrast-enhanced ultrasound |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689529/ https://www.ncbi.nlm.nih.gov/pubmed/36359506 http://dx.doi.org/10.3390/diagnostics12112662 |
work_keys_str_mv | AT luxiuyun earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT guoxi earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT zhangqi earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT qiuyijie earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT zuodan earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT chensheng earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT tianxiaofan earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT zhouyuhong earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT dongyi earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound AT wangwenping earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound |